Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in rod photoreceptor cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 166 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12443
Sealed predictions
- CADM2 in oligodendrocytes, braak+0.48 (p 0.193) → +0.24 (p 0.535)receipt 12451
- CADM2 in dopamine neurons, braak+0.16 (p 0.685) → +0.39 (p 0.304)receipt 12452
Swarm cases
receipt 12452: CADM2 in dopamine neurons, braak
- power
- full sample +0.27 (p 0.281, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.243, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.30 (p 0.232, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.41, sign flips 0; without severely affected donors +0.27 (p 0.281, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CADM2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 12451: CADM2 in oligodendrocytes, braak
- power
- full sample +0.17 (p 0.493, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.18 (p 0.482, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.20 (p 0.418, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.29, sign flips 0; without severely affected donors +0.17 (p 0.493, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CADM2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts